Ketorolac PatchPump - SteadyMed Therapeutics

Drug Profile

Ketorolac PatchPump - SteadyMed Therapeutics

Alternative Names: SMT-201

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SteadyMed Therapeutics
  • Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 12 Oct 2017 SteadyMed receives patent allowance for PatchPump® infusion system in Europe
  • 02 May 2017 SteadyMed receives Notice of Allowance for PatchPump® infusion system in USA
  • 28 Oct 2015 Final pharmacokinetics data from a phase-I trial in Pain released by SteadyMed Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top